Sonoma Pharmaceuticals (SNOA) Depreciation & Amortization (CF) (2016 - 2025)
Sonoma Pharmaceuticals has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $34000.0 for Q4 2025.
- For Q4 2025, Depreciation & Amortization (CF) rose 3.03% year-over-year to $34000.0; the TTM value through Dec 2025 reached $137000.0, down 7.43%, while the annual FY2025 figure was $138000.0, 21.59% down from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $34000.0 at Sonoma Pharmaceuticals, down from $36000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $52000.0 in Q3 2021 and troughed at $28000.0 in Q3 2022.
- A 5-year average of $38550.0 and a median of $36500.0 in 2021 define the central range for Depreciation & Amortization (CF).
- Biggest five-year swings in Depreciation & Amortization (CF): tumbled 60.0% in 2021 and later surged 60.71% in 2023.
- Year by year, Depreciation & Amortization (CF) stood at $37000.0 in 2021, then dropped by 13.51% to $32000.0 in 2022, then soared by 40.62% to $45000.0 in 2023, then fell by 26.67% to $33000.0 in 2024, then grew by 3.03% to $34000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for SNOA at $34000.0 in Q4 2025, $36000.0 in Q3 2025, and $36000.0 in Q2 2025.